Neovacs

21c Bio

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Medecine Et Innovation

Neovacs S.a.

Université Paris Diderot-Paris 7

UniversitÉ De Paris

Daniel Zagury

Bernard Bizzini

Helene Le Buanec

Jean-François Zagury

Hélène Le Buanec

Armand Bensussan

Jean-Francois Zagury

Sophie Duchez

Helene Le Buannec

Jean-Fran&ccedil;ois Zagury

Valerie Schiavon

Jean-Francedillaois Zagury

Jean Francois Zagury

Jean-Claude Maziere

Jean-Charles Landureau

Amar Achour

Jean François Zagury

A method for treating acquired immune deficiency syndrome (AIDS) in a subject in need thereof. In particular, the method includes the administration of a combination, a kit-of-parts, a composition or a pharmaceutical composition including an interferon-alpha (IFN-α) blocking agent, a type III interferon blocking agent, an antiretroviral (ART) agent and, optionally, an interferon-beta (IFN-β) blocking agent and/or a latency-reversing agent (LRA).

Method of inhibiting HIV-1 viral rebound in a subject using interferon inhibitors and ART

A method for preventing an infectious disease in a subject in need thereof. In particular the method includes the administration of a combination, pharmaceutical combination, medicament or kit-of-parts including a first part including a CD8 vaccine specific for at least one infectious disease-related antigen, optionally a second part including an interferon alpha blocking agent, and a third part including a type III interferon and/or an agent stimulating the production of type III interferon.

Vaccine to pathogenic immune activation cells during infections

The present invention relates to a method for ex vivo generating and expanding MHCII restricted CD4Foxp3regulatory T cells, and therapeutic uses thereof. The inventors here demonstrated the optimal conditions for inducing Foxp3 expression in naive CD3+ CD4+ TCR&#x3b1;&#x3b2;+ MHCII restricted T following polyclonal or following antigen-specific activation. They also developed an experimental procedure to generate autologous CD8+ T cell lines functionally committed to lyse tumor-antigen specific FOXP3 expressing TCR&#x3b1;&#x3b2;+ MHCII restricted T cells, pathogenic CD4+ T cells that favour tumor cell immune evasion. In particular, the present invention relates to a method for generating ex vivo MHCII restricted CD4+ Foxp3+ regulatory T cells having the following phenotype: CD3+ CD4+ Foxp3+.

Ex vivo generation of MHCII restricted CD4FOXP3regulatory T cells and therapeutic uses thereof

The present invention relates to a method for ex vivo generating and expanding &#x3b3;&#x3b4; Foxp3regulatory T cells, and therapeutic uses thereof. The inventors performed the induction of Foxp3+ expression in ex vivo human induced tumor-antigen specific CD4+ TCR&#x3b3;&#x3b4; unrestricted T cells and the induction of autologous CD8-mediated T-cell responses against tumor-antigen specific FOXP3 expressing CD4+ TCR&#x3b3;&#x3b4; unrestricted T cells. The inventors developed a method to ex vivo generated and expanded antigen specific Foxp3 expressing CD3+ TCR&#x3b3;&#x3b4;+ unrestricted T cells, committed to exclusively exert regulatory activity, whichever culture condition of stimulation is. In particular, the present invention relates to a method for generating ex vivo &#x3b3;&#x3b4; Foxp3+ regulatory T cells having the following phenotype: CD3+ TCR&#x3b3;&#x3b4;+ Foxp3+.

Ex vivo generation of &#x3b3;&#x3b4; Foxp3regulatory T cells and therapeutic uses thereof

In the present invention, the Applicant provides a novel method for preventing or treating an infectious disease in a subject in need thereof. In particular said method comprise the administration of a combination, pharmaceutical combination, medicament or kit-of-parts comprising a first part comprising a CD8 vaccine specific for at least one infectious disease-related antigen, optionally a second part comprising an interferon alpha blocking agent, and a third part comprising a type III interferon and/or an agent stimulating the production of type III interferon.

A novel method for preventing or treating an infectious disease in a subject in need thereof. In particular the method includes the administration of a combination, pharmaceutical combination, medicament or kit-of-parts having a first part including a CD8 vaccine specific for at least one infectious disease-related antigen, a second part including an agent neutralizing circulating alpha interferon and/or an agent blocking interferon alpha signaling, and/or a third part including a type III interferon and/or an agent stimulating the production of type III interferon.

The invention relates to a stable immunogenic product for the induction of antibodies against one or more antigenic proteins in a subject. The invention is characterized in that it comprises proteinaceous immunogenic heterocomplexes which are formed by associations between (i) antigenic protein molecules and (ii) proteinaceous carrier molecules and in that less than 40% of the antigenic proteins (i) are linked to the proteinaceous carrier molecules (ii) by a covalent bond.

Stable immunogenic product comprising antigenic heterocomplexes

The invention concerns a pharmaceutical composition comprising, as the active ingredient, human natural antibodies of the IgG isotype, that neutralize the activity of a human cytokine selected from VEGF, IFN&#x3b1;, IL-4, TNF&#x3b1; and TGF&#x3b2;, the said neutralizing antibodies inhibiting at least 50% of the maximum biological activity induced by an amount ranging from 0.006 ng to 0.05 ng of the said cytokine in vitro.

High-yield method for the production of human antibodies blocking the biological activity of a human cytokine

A stable immunogenic product for the induction of antibodies against one or more antigenic proteins in a subject, characterized in that it comprises proteinaceous immunogenic heterocomplexes which are formed by associations between (i) antigenic protein molecules and (ii) proteinaceous carrier molecules and in that less than 40% of the antigenic proteins (i) are linked to the proteinaceous carrier molecules (ii) by a covalent bond.

Method for preparing a stable TNF-&#x3b1; vaccine

The invention concerns vaccines comprising as an active principle an immunogen which is a cytokinetic factor or a cell regulating factor particularly transcriptional or another type of factor with immunosuppressive/apoptotic/angiogenic properties abnormally released in the extracellular (stromal) environment by cancer or stromal cells of malignant tumors, and a pharmaceutically acceptable carrier for inducing a systemic or mucosal immune response with secretory formation of class IgC or IgA neutralizing antibodies directed against the native factor, or which is derived from such a factor and the use of said immunogen to obtain a medicine for use as anticancer drug.

Use of immunogens to treat or prevent, in malignant tumors, the immune or vascular disorders induced by extracellular factors

The invention relates to a stable immunogenic product for the induction of antibodies against one or more antigenic proteins in a subject. The invention is characterised in that it comprises proteinaceous immunogenic heterocomplexes which are formed by associations between (i) antigenic protein molecules and (ii) proteinaceous carrier molecules and in that less than 40% of the antigenic proteins (i) are linked to the proteinaceous carrier molecules (ii) by a covalent bond.

The present invention concerns a novel method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNF&#x3b1; and a carrier protein, the method steps of which are disclosed in the specification.

Method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNF&#x3b1; and a carrier protein

An immumogenic polypeptide for inducing antibodies that neutralize the immunosuppressive and/or angiogenic activity of an E7 protein from Papillomavirus, wherein said immunogenic polypeptide consists of an E7 protein from Papillomavirus that has been inactivated so as to eliminate at least 70% of the immunosuppressive and/or angiogenic activity of the non-inactivated E7 protein. The inactivation is effected by physical and/or chemical treatments and/or by modification of the amino acid sequence of the polypeptide.

Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses

A method for inducing a mucosal immunity with production of secretory IgA antibodies that neutralize of block a native E7 protein originating from cancerous cells, from cells infected by a human Papillomavirus or from an immune system cell. The method includes administering to a patient in need thereof, a vaccine composition containing an active compound which is the native E7 protein, the properties of which have been inactivated by at least 70% by a physical and/or a chemical treatment, by genetic recombination or by adjuvant conditions; an inactive fragment of the immunosuppressive and/or angiogenic native E7 protein; a DNA molecule encoding the immunosuppressive and/or angiogenic native E7 protein inactivated by at least 70% by mutation; or a DNA molecule encoding an inactive fragment of the immunosuppressive and/or angiogenic native E7 protein; along with an adjuvant of mucosal immunity.

Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory IgA's

The invention relates to an immunogenic or vaccine composition inducing an immune response towards the HPV-16 Papillomavirus native E7 protein, without simultaneously inducing an immunosuppression, said composition comprising, as the active ingredient, a non immunosuppressive mutated E7 protein, comprising the amino acid sequence consisting, from the N-terminal end to the C-terminal end, in:

Growing community of inventors

Paris, France

Daniel Zagury